Podcasts about Moderna

Angel Studios https://Angel.com/HermanJoin the Angel Guild today where you can stream Thank You, Dr. Fauci and be part of the conversation demanding truth and accountability.  Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comBe confident in your portfolio with Bulwark! Schedule your free Know Your Risk Portfolio review. Go to KnowYourRiskPodcast.com today. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/ToddThe new GOLDEN AGE is here! Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeJenner Furst, director of the latest Angel Studios documentary "Thank You Dr. Fauci" joins the show.Episode Links:Thank You Dr. Fauci | Now Streaming | AngelBREAKING/URGENT: mRNA COVID VACCINES KILLED AT LEAST 10 KIDS, THE FDA REPORTS; An FDA review found the shots to blame for the deaths, FDA's new vaccine chief - Dr. Vinay Prasad - told staffers in an email. The agency will tighten standards on new vaccine approval, Prasad wrote.Fauci's Ebola stuntURGENT: mRNA Covid jabs should NEVER have been approved for children or young adults Pfizer, Moderna, the Biden Administration, and everyone in public health who pushed these for kids and teens have blood on their handsUnmask The Truth | Official Clip | Thank You, Dr. Fauci

Fue todo un icono del cuplé, de la cultura y de la sofisticación. Hoy traemos a nuestro cronovisor la figura de la Fornarina. Jesús Callejo nos hablará de todos sus secretos. Luego viajamos a Córdoba para visitar la exposición El despertar a la vida, en donde se nos describe cómo era la vida de los niños y niñas en el antiguo Egipto. Lo hacemos con una de sus comisarias, la egiptóloga Esther Pons. Miguel Lázaro nos trae una nueva sección de Discos con historia de la mano de Led Zeppelin. Acabamos el programa en la guerra de Vietnam con David López Cabia, quien acaba de publicar Callejones sin gloria en donde se nos cuenta la historia de la batalla de Hue

Te invitamos a escucharnos todos los viernes en punto de las 18:00hrs. En compañía de Jorge Escamilla H. presentando su programa La sociedad Moderna- Nuevas formas de amar Compártenos tus comentarios y síguenos en nuestras redes sociales. Proyecto Radio MX, con Sentido Social

Paypal: https://www.paypal.com/paypalme/editorialtpv El día de hoy hablaremos sobre el capítulo 4 del libro The Oxford Handbook of Christmas, titulado “The Nineteenth Century,” por Timothy Larsen. Ver aquí: https://global.oup.com/academic/product/the-oxford-handbook-of-christmas-9780198831464?cc=gb&lang=en& Articulo: https://semperreformandaperu.org/2025/12/19/como-el-siglo-xix-realmente-invento-la-navidad/ Video: https://youtu.be/LpY9bkOnO78  PPT: https://semperreformandaperu.org/wp-content/uploads/2025/12/navidad_el_rio_de_cuatro_corrientes.pdf  ¿De verdad la Navidad estaba muriendo antes de 1843 y Charles Dickens la resucitó? Este episodio entra en el siglo XIX para poner esa historia contra la evidencia. A partir del capítulo “The Nineteenth Century”, seguimos cómo la Navidad ya era una festividad importante en Inglaterra en las primeras décadas del siglo, y cómo ciertos argumentos “clásicos” (por ejemplo, el supuesto silencio anual de The Times) se desmoronan al revisar los datos y el contexto editorial de la época.   Luego examinamos lo que sí cambió: la expansión y reconfiguración de la fiesta en clave victoriana. La Navidad se volvió más amplia y más densa: crecieron sus marcas domésticas (familia, infancia, regalos, árbol), su infraestructura cultural (villancicos, decoración, tarjetas), y su dimensión moral (caridad y responsabilidad social en un mundo industrial).   El capítulo también muestra un giro poco reconocido: la progresiva aceptación de la Navidad por parte de protestantes reformados y disidentes, que antes la rechazaban como “no bíblica”, pero terminaron incorporándola —a veces por la presión social, a veces por dinámicas de ministerio infantil y escuela dominical.   Finalmente, rastreamos dos símbolos decisivos: Santa Claus y el árbol, ambos difundidos en gran medida por redes cristianas y por tradiciones protestantes alemanas. La Navidad moderna no nació de la nada: fue una transformación acumulativa. 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of groundbreaking advancements, revealing a landscape rich with scientific innovation and strategic maneuvers poised to impact patient care and the drug development pipeline.Let's start with Johnson & Johnson's recent FDA approval for a subcutaneous version of Rybrevant, their lung cancer medication. This new formulation offers a more convenient administration method compared to AstraZeneca's Tagrisso, intensifying competition in the non-small cell lung cancer market. The shift towards more patient-friendly delivery systems underscores the industry's commitment to enhancing treatment adherence and convenience. In contrast, Insmed faced a setback with its phase 2 trial for Brinsupri in treating chronic rhinosinusitis without nasal polyps. The discontinuation of this program highlights the unpredictable nature of clinical trials and emphasizes the need for rigorous scientific validation before advancing therapeutic candidates.Meanwhile, Lilly has shown promising results with its oral obesity pill, marking significant progress in weight management therapies. Patients transitioning from injectable GLP-1 therapies to Lilly's oral drug candidate maintained substantial weight loss, positioning Lilly favorably against Novo Nordisk's Wegovy. The potential for oral formulations to revolutionize treatment paradigms in chronic conditions cannot be understated. Lilly's progress in obesity treatment with its oral medication orforglipron further cements its competitive edge. Participants in their Phase III clinical trial maintained weight loss after switching from Wegovy or Zepbound to orforglipron, suggesting an efficacious oral alternative to injectable treatments and potentially enhancing patient adherence.On the regulatory front, the Biosecure Act's progression within a major defense spending bill could impose new challenges for life sciences companies with Chinese affiliations. This legislative shift reflects geopolitical tensions impacting global pharmaceutical collaborations and underscores the importance of regulatory compliance in international partnerships. Similarly, Intercept Pharmaceuticals' restructuring following the withdrawal of Ocaliva from the U.S. market is indicative of strategic pivots in response to regulatory hurdles and evolving market dynamics.In dermatology, Takeda's successful phase 3 trials for Zasocitinib highlight the competitive nature of drug development as multiple players vie for market share within therapeutic areas. Their anticipated 2026 FDA filing underscores the prolonged timelines involved in bringing novel therapies to market despite successful clinical outcomes.Public-private collaborations continue to play a crucial role in vaccine development, as evidenced by Moderna's pandemic influenza vaccine advancement into phase 3 trials with support from the Coalition for Epidemic Preparedness Innovations (CEPI). This $54 million investment illustrates ongoing efforts to bolster pandemic preparedness through innovative mRNA technologies. Meanwhile, Moderna's $54 million funding from CEPI to advance its bird flu vaccine highlights resilience amidst fluctuating governmental support. This endeavor leverages Moderna's mRNA technology platform, emphasizing mRNA's versatility across various infectious diseases.Shifting our focus slightly, medical groups have expressed opposition to changes in hepatitis B vaccination recommendations by the CDC for newborns. Such policy debates have significant implications for public health strategies and highlight ongoing discussions within medical communities regarding optimal vaccination protocols.GSK's strategic collaboration with Camp4 Therapeutics marks another key industry development. With an investment exceeding $400 million, GSK aims to Support the show

“People are not looking for a perfect, polished answer. They're looking for a human to speak to them like a human,” says Jessica Malaty Rivera, an infectious disease epidemiologist and one of the most trusted science communicators in the U.S. to emerge from the COVID-19 pandemic. That philosophy explains her relatable, judgement-free approach to communications which aims to make science more human, more accessible and less institutional. In this wide-ranging Raise the Line discussion, host Lindsey Smith taps Rivera's expertise on how to elevate science understanding, build public trust, and equip people to recognize disinformation. She is also keen to help people understand the nuances of misinformation -- which she is careful to define – and the emotional drivers behind it in order to contain the “infodemics” that complicate battling epidemics and other public health threats. It's a thoughtful call to educate the general public about the science of information as well as the science behind medicine. Tune in for Rivera's take on the promise and peril of AI-generated content, why clinicians should see communication as part of their professional responsibility, and how to prepare children to navigate an increasingly complex information ecosystem.Mentioned in this episode:de Beaumont Foundation If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

El rol del consultor debe de ser como el del "médico internista" que diagnostica los problemas generales de una empresa antes de que intervengan especialistas. Marian Pérez destaca la importancia de la flexibilidad, la planificación y la visión a largo plazo para que las PYMES se adapten al entorno económico actual, marcado por la incertidumbre y la necesidad de modelos organizativos flexibles. Un tema central es la gestión del talento, incluyendo la retención y la captación, y la necesidad de integrar los talentos joven y senior a través de diferentes modelos de colaboración, un desafío aún presente en la cultura empresarial española. Finalmente, se discute la importancia de la comunicación transparente y la profesionalización de la gestión en las empresas familiares, distinguiendo claramente entre familia, propiedad y administración.

Le prime pagine dei principali quotidiani nazionali commentate in rassegna stampa da Davide Giacalone. Le tensioni nel governo sulle pensioni, Putin insulta i leader europei definendoli maiali approfittatori, Salvini e il caso Open Arms, le nuove regole dei condomini. Con Myriam De Filippi, di Donna Moderna. abbiamo parlato di denatalità, con alcuni dati pubblicati nel numero in edicola. Spazio Psicologia. Torniamo a collegarci con Raffaele Morelli, psicologo e psicoterapeuta, in libreria con "Abbiamo perso l'anima. Ecco perché soffriamo e come guarire" (Edito da Mondadori). Don Antonio Mazzi, fondatore della comunità Exodus, regala ogni giorno un pensiero, un suggerimento, una frase agli ascoltatori di RTL 102.5. In diretta Gianluigi Nuzzi per parlare dei principali casi di cronaca nera e del suo tour teatrale. Manca poco a Natale e tanti very normal people in ritardo con i regali si rifugiano nelle soluzioni dell'ultimo minuto: sciarpe, guanti, calzini... Servirebbe qualche suggerimento per andare oltre a questi doni abbastanza tristi. Ci siamo fatti dare qualche idea da Angelo Ruggeri, professore e giornalista di moda. L'attualità , commentata dall'editorialista del Corriere della Sera, Ferruccio De Bortoli. All'interno di Non Stop News, con Enrico Galletti, Massimo Lo Nigro e Lucrezia Bernardo.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über ein Ausnahmejahr für Rückversicherer, einen Dämpfer für Rüstungsaktien und Enttäuschung bei Pfizer. Außerdem geht es um Rheinmetall, Renk, Hensoldt, Lufthansa, Easyjet, Warner Bros Discovery, Paramount Skydance, Netflix Pfizer, Moderna, Biontech, Tilray Brands, Swiss Re, Munich Re, Hannover Rück, iShares S&P 500 Insurance ETF (WKN: A0H08K), Rize USA Environmental Impact UCITS ETF (WKN: A3ENMA), iShares MSCI Climate Transition Aware UCITS ETF (WKN: 906866), Lyxor MSCI Green Infrastructure ETF (WKN: LYX0YL), VanEck Sustainable Infrastructure ETF (WKN: A12HWR), Teva Pharmaceutical, Bank Leumi, Bank Hapoalim, Elbit Systems und Check Point Software. Die aktuelle "Alles auf Aktien"-Umfrage findet Ihr unter: https://www.umfrageonline.com/c/mh9uebwm Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Si la Biblia es la Palabra de Dios, ¿por qué no menciona temas científicos modernos como la capa de ozono, la genética, el calentamiento global o la posibilidad de vida extraterrestre?En este episodio explicamos qué es la Biblia, cuál es su propósito real y por qué no debemos esperar que responda preguntas científicas contemporáneas. También exploramos la relación entre revelación divina, ciencia y adoración.Envía tus preguntas a: preguntas@verdadyfe.comConecta con nosotros aquí: https://linktr.ee/verdadyfe

✨ Apoya nuestro podcast y disfruta sin interrupciones ✨ Si valoras nuestro contenido, ayúdanos a seguir creando más episodios y, como agradecimiento, escucha Estoicismo Filosofía Premium sin anuncios.

Masada-klippan och den befästa fästningen där de judiska seloterna gjorde sitt sista motstånd mot Romarriket har en närmast mytologisk betydelse i dagens Israel. Fortfarande svär unga israeliska soldater sin trohet uppe på Masada – en plats som blivit en symbol för motstånd, offer och nationell identitet.Det judiska upproret, som inleddes år 66 e.Kr., blev en katastrof för det judiska folket. År 70 förstördes Jerusalem i grunden av romarna, och den sista fasen av upproret utspelade sig på Masada. Under åren 73–74 belägrades fästningen av den romerska armén i en militär operation som fortfarande imponerar historiker. Genom att anlägga en enorm ramp uppför berget och omringa platsen med ett system av läger och vallar tvingade romarna de judiska försvararna till ett sista desperat beslut.I detta avsnitt av Militärhistoriepodden diskuterar Martin Hårdstedt och Peter Bennesved den dramatiska slutstriden vid Masada. Belägringen är inte bara central i berättelsen om de judiska upproren, utan även ett unikt exempel på romersk belägringsteknik. Rester av romarnas anläggningar – vallarna, lägren och framför allt den väldiga rampen – finns ännu kvar och ger oss en sällsynt inblick i antikens krigskonst.Den mest omdiskuterade aspekten av Masada är berättelsen om det kollektiva självmord som enligt den judiske historikern Flavius Josefus ska ha ägt rum, där seloterna valde döden framför romerskt slaveri. Men hur pålitlig är denna källa? Moderna forskare menar att berättelsen måste tolkas med försiktighet – det finns inga oberoende bekräftelser på att självmordet faktiskt ägde rum.Konsekvenserna av de judiska upproren blev ödesdigra. Det judiska folket skingrades, och en lång exil inleddes. Först mot slutet av 1800-talet väcktes idén om en återkomst till det historiska hemlandet, och det var först år 1948 som staten Israel grundades. Masada lever kvar – som symbol och myt, men också som ett fysiskt monument över romersk krigföring och judiskt motstånd.Bildtext: Masada är en symbol för judiskt motstånd och är mest känd för det romerska belägringsdramat år 73 e.Kr. Platsen är idag ett världsberömt arkeologiskt monument och ett UNESCO-världsarv. Foto: Andrew Shiva / Wikipedia. Licens: CC BY-SA 4.0.Klippare: Emanuel Lehtonen Hosted on Acast. See acast.com/privacy for more information.

Algunas producciones de la etiqueta norteamericana Víctor, editadas en la frontera de los años 30 a los 40 del siglo XX, nos permitirán revivir el fenómeno de la "cubanización" de las orquestas jazz bands. La orquesta Hermanos Castro con su cantante Miguelito García, Miguelito Valdés con la Casino de la Playa, Cascarita con la orquesta Hermanos Palau y Reinaldo Valdés "el jabao" con la orquesta del trompetista Julio Cueva nos acercan algunos clásicos de la música popular cubana. A continuación, y a propósito de la evolución de los jazz bands en la isla, un recuerdo para uno de los grandes artífices de este formato orquestal: el pianista, arreglista y compositor Ernesto Duarte. Fernando González, Tata Ramos y Rolo Martinez, grabados y producidos por el talentoso músico para su etiqueta "Duarte" llegan con la sonoridad del jazz band de los últimos años 50. Junto al contrabajista Cachao López y otros notables instrumentistas como Alejandro "el negro" Vivar en trompeta, Generoso "Tojo" Jiménez en trombón, Rogelio "Yeyito" Iglesias en los bongoes, Guillermo Barreto en pailas, Niño Rivera en el tres, Tata Güines en las tumbadoras, volvemos a los míticos estudios de Panart y a las "descargas en miniatura" que, finalizando los 50, permitieron cristalizar la categoría del jazz en el panorama discográfico cubano. En ese sentido las producciones "Tropicana", propiciadas por el genio de la emisora CMOX: Adolfo Seeman, constituyeron un paso más en el desarrollo en la discografia en función de darle más consistencia a la llamada "descarga". Frank Emilio a la cabeza del "Quinteto de Música Moderna", impulsado comercialmente por Seeman, con la complicidad de Papito Hernández en contrabajo, Gustavo Tamayo en güiro, Tata Güines en las tumbadoras y Guillermo Barreto en drum y pailas. En la despedida, y de vuelta al catálogo RCA Víctor, revisitamos el debut discográfico del Benny Moré como parte del conjunto Matamoros. Las maravillas de la música popular cubana, todos los domingos, las reservamos aquí para ti.

Te invitamos a escucharnos todos los viernes en punto de las 18:00hrs. En compañía de Jorge Escamilla H. presentando su programa La sociedad Moderna- planeación estrategia inteligente Compártenos tus comentarios y síguenos en nuestras redes sociales. Proyecto Radio MX, con Sentido Social

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a myriad of transformative advancements and strategic shifts within these industries, illustrating the profound impact of innovation and regulatory changes on healthcare.Eli Lilly's recent strides in obesity treatment highlight a significant scientific breakthrough with their novel drug, retatrutide. Currently in phase 3 trials, this triple agonist targets GLP-1, GIP, and glucagon receptors, achieving an extraordinary 28.7% weight loss in participants. Additionally, it demonstrated a 75.8% reduction in knee osteoarthritis pain. Yet, the journey to this milestone wasn't without challenges. The trials saw a higher discontinuation rate than earlier studies, reminding us of the delicate balance between efficacy and patient tolerability—a consistent theme in obesity pharmacotherapy as developers strive to maximize benefits while minimizing adverse effects.In a testament to the global nature of drug development, Zealand Pharma has embarked on a $2.5 billion collaboration with a burgeoning Chinese biotech firm. This partnership aims to advance oral cardiometabolic therapies, underscoring the crucial role of strategic alliances in accessing innovative scientific platforms and expanding market reach.Rezolute faced a significant setback with a disappointing phase 3 trial for its hypoglycemia treatment, resulting in an 87% drop in stock value. This starkly illustrates biotech's inherent volatility and the critical importance of robust clinical trial design to mitigate financial risks associated with unsuccessful outcomes.Meanwhile, Moderna is leveraging Nanexa's expertise in long-acting formulations to enhance injectable therapy delivery systems. This collaboration is indicative of a broader industry trend focused on optimizing drug delivery technologies to boost efficacy and patient compliance.Operational restructuring is also evident as Pfizer implements cost-cutting measures, including layoffs in Switzerland, as part of broader strategic initiatives to optimize operations amid rising R&D costs and pricing pressures. Simultaneously, Chris Boulton's transition from Amgen to Prolynx underscores the fluid movement of talent within the industry—a reflection of ongoing strategic realignments.Regulatory landscapes are shifting as well. The FDA's approval of the first non-drug at-home treatment for depression marks an expansion into alternative therapeutic modalities beyond traditional pharmaceuticals. This wearable device offers adults with major depressive disorder a novel treatment option, integrating technology into mental health care—a promising addition to holistic treatment strategies.In another significant regulatory update, Teva Pharmaceuticals agreed to delist numerous patents from the FDA's Orange Book following an FTC ruling. This move is anticipated to foster increased generic competition and potentially lower medication costs for conditions like asthma and diabetes—a critical shift towards greater market accessibility.The FDA has also finalized guidance on promotional materials for biologics and biosimilars, standardizing advertising practices to ensure accurate representation of these products' efficacy and safety profiles amidst an expanding biologics market.Moreover, the FDA has launched its Commissioner's National Priority Voucher Pilot Review Program to expedite critical drug approvals. The first beneficiary under this program was USAntibiotics with Augmentin XR, signaling a potential shift towards more rapid access to essential medications.On the international policy front, recent developments between the UK and US have led to reductions in medicine rebate rates within the UK. This adjustment could lead to increased spending on new medicines, indicating more favorable conditions for pharmaceutical Support the show

“Delivering a baby one day and holding a patient's hand at the end of life literally the next day...that continuity is very powerful,” says Dr. Jen Brull, board chair of the American Academy of Family Physicians (AAFP). And as she points out, that continuity also builds trust with patients, an increasingly valuable commodity when faith in medicine and science is declining. As you might expect given her role, Dr. Brull believes strengthening family medicine is the key to improving health and healthcare. Exactly how to do that is at the heart of her conversation with host Lindsey Smith on this episode of Raise the Line, which covers ideas for payment reform, reducing administrative burdens, and stronger support for physician well-being. And with a projected shortage of nearly forty thousand primary care physicians, Dr. Brull also shares details on AAFP's “Be There First” initiative which is designed to attract service-minded medical students – whom she describes as family physicians at heart -- early in their educational journey. “I have great hope that increasing the number of these service-first medical students will fill part of this gap.”Tune-in for an informative look at a cornerstone of the healthcare system and what it means to communities of all sizes throughout the nation.  Mentioned in this episode:AAFP If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Le prime pagine dei principali quotidiani nazionali commentate in rassegna stampa da Davide Giacalone. Il decreto mille proroghe, come entrare in America, donatore di sperma e mutazione genetica, l'Europa in pressing su Trump. Spazio Donna Moderna. L'approfondimento di oggi ha il titolo: "Sai tenere un segreto?". Con Marta Bonini, vicecaporedattrice di Donna Moderna. Spazio Calcio. Le nostre italiane in Europa con i nostri inviati. ⁠Commento Benfica-Napoli con Paolo Pacchioni. Commento Juventus-Pafos con Andrea Salvati. Presentazione Celtic-Roma di Europa League, da Glasgow Tommaso Angelini. Don Antonio Mazzi, fondatore della comunità Exodus, regala ogni giorno un pensiero, un suggerimento, una frase agli ascoltatori di RTL 102.5. Scuola. In questi giorni è stato pubblicato un vademecuum del Garante della Privacy per cercare di capire come è corretto comportarsi in un'epoca dominata da intelligenza artificiale, registri elettronici, chat su Whatsapp. Il punto con Antonello Giannelli, presidente dell'Associazione Nazionale Presidi. Migranti. L'UE lavora al patto per la migrazione e l'asilo e proprio pochi giorni fa i ministri degli interni, riuniti in Consiglio, hanno dato il via libera a una serie di provvedimenti: nuove procedure di rimpatrio, una lista di Paesi cosiddetti "sicuri", ecc. Capiamo cosa cambierà effettivamente con l'avvocato Salvatore Fachìle, esperto di diritto di asilo, membro del consiglio direttivo dell'Associazione Studi Giuridici sull'Immigrazione. L'attualità, commentata dal direttore de Il Giornale, Tommaso Cerno. All'interno di Non Stop News, con Enrico Galletti, Massimo Lo Nigro e Lucrezia Bernardo.

Recibe tu curso gratis aquí: https://www.hombrealfa.top/curso-gratis/ Únete a los miles de hombres que forman parte de mi comunidad de email para acceder a promociones exclusivas y enterarte de la apertura de mis formaciones. Estar suscrito tiene premio y es la única manera de estar al día de las novedades del proyecto. Al suscribirte con tu email, recibes el curso gratis de «Cómo ser un hombre más atractivo e interesante para las mujeres en la era de las apps y las redes sociales». Es un curso de siete lecciones por escrito (no vídeo, no audio) que puedes personalizar en función del momento que estés viviendo en tus relaciones. Para unirte a mi comunidad y recibir el curso, deja tu email en el enlace: https://www.hombrealfa.top/curso-gratis/ *¿Qué aprenderás en este episodio?: 1) El error más común que cometen incluso los hombres casados durante décadas. 2) Por qué una mujer puede quererte... y aun así irse con otro. 3) La verdad biológica que ningún gurú Red Pill se atreve a decirte. 4) Cómo cambia el deseo femenino según su ciclo menstrual (y por qué deberías saberlo). 5) Qué debes entender (y desaprender) para elegir una relación monógama desde tu marco. En este episodio desenmascaramos uno de los mayores tabúes que existen hoy sobre las mujeres: su estrategia reproductiva dual. ¿De verdad buscan al chico malo solo cuando son jóvenes? ¿Y qué pasa cuando se casan? ¿Cambian realmente sus preferencias? Vamos a tirar abajo décadas de cuentos femeninos y falsas Red Pill basándonos solo en biología evolutiva y estudios reales. Porque si no entiendes la hipergamia desde la raíz, acabarás como tantos hombres: perdido, traicionado y sin saber qué ha fallado. PD. Recibe tu curso gratis aquí: https://www.hombrealfa.top/curso-gratis/

Le prime pagine dei principali quotidiani nazionali commentate in rassegna stampa da Davide Giacalone. Trump e l'ultimatum a Kiev, gli ospedali italiani promossi, De Luca su Falcone e Borsellino, Spazio Donna Moderna. Sul sito del settimanale c'è un interessante approfondimento dal titolo: "Parlare da soli: l'arte segreta di restare in bolla”. Con noi in diretta Paola Salvatore, di Donna Moderna. Intesa Sanpaolo apre al pubblico dal 28 novembre 2025 al 6 aprile 2026, nel suo museo di Milano delle Gallerie d'Italia, la mostra "Eterno e visione. Roma e Milano capitali del Neoclassicismo" a cura di Francesco Leone, Elena Lissoni e Fernando Mazzocca. Ci siamo collegati con Francesco Leone, curatore della mostra "Eterno e visione. Roma e Milano capitali del Neoclassicismo". Don Antonio Mazzi, fondatore della comunità Exodus, regala ogni giorno un pensiero, un suggerimento, una frase agli ascoltatori di RTL 102.5. Mancano poche ore al verdetto che dovrebbe decretare la cucina italiana Patrimonio immateriale dell'Unesco. Ci siamo collegati con l'India, dove c'è Maddalena Fossati, direttrice de "La cucina italiana" e presidente del Comitato Promotore per la candidatura della Cucina Italiana come patrimonio culturale immateriale dell'umanità UNESCO, e con il sottosegretario alla cultura, Gianmarco Mazzi. Abbiamo rivissuto tutte le emozioni della serata in Champions e abbiamo parlato delle partite che oggi vedono impegnate le italiane. Highlight di Atalanta Chelsea, commento Atalanta con Massimo Caputi. Highlight di Inter Liverpool, commento Inter e presentazione Benfica Napoli con Paolo Pacchioni. Presentazione Juventus Pafos con Andrea Salvati. L'attualità economica, commentata dal prof. carlo cottarelli, economista. All'interno di Non Stop News, con Enrico Galletti, Massimo Lo Nigro e Lucrezia Bernardo.

Dirige y presenta: Juan Carlos Baruque Hernández Sumario del programa MIGUEL ÁNGEL RUIZ *Las nuevas conspiraciones. *Conspiraciones modernas. Nuestra Web: https://mundoinsolitoradio.es Contacta: +34 687 39 80 12 - Solo WhatsApp mundoinsolitoradio@hotmail.com Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

Michael Jordan never won an NBA championship until he was paired with the right coach. Then, he won six. Could working with a coach change your MS journey? In this week's episode, health & wellness coach Amy Behimer explains what health coaching is all about and how working with a coach might impact someone living with MS. We're also sharing study results that show DMTs fail to manage MS-related pain. Then, we'll explain how a common misconception can lead to the wrong outcome for someone with MS. And we'll share study results showing that adhering to the Mediterranean or MIND diet improves cognitive performance among people living with MS. We'll also explain why this study raises as many questions as it seeks to answer. We have a lot to talk about! Are you ready for RealTalk MS??! Thank you!  :22 This Week: What working with a health coach is all about  1:08 Study results show that disease-modifying therapies don't help manage MS-related pain (But are they supposed to???)  2:29 Study results show that adhering to the Mediterranean or MIND diet improves cognitive performance among people with MS (Or does it??)  5:13 Health & Wellness Coach Amy Behimer explains how someone living with MS could benefit from coaching  12:11 Share this episode  39:33 Next week's episode  39:53 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/432 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com DONATE: The National MS Society https://nationalmssociety.org/donate SIGN UP: Become an MS Activist https://nationalmssociety.org/advocacy STUDY: Phase 2 Clinical Trial for Moderna's EBV Vaccine and MS https://www.msard-journal.com/article/S2211-0348(25)00573-5/fulltext STUDY: Mediterranean and MIND Diet Patterns and Cognitive Performance in Multiple Sclerosis: A Cross-Sectional Analysis of the UK Multiple Sclerosis Register https://www.mdpi.com/2072-6643/17/21/3326 JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 432 Guests: Amy Behimer Privacy Policy

Per approfondire gli argomenti della puntata: Altre pillole dedicate all'Età Moderna : https://www.youtube.com/watch?v=04jMzzw0qK4&list=PLpMrMjMIcOkkxE3VRfoFOph9H6S2v2Njr&ab_channel=LaBibliotecadiAlessandria Learn more about your ad choices. Visit megaphone.fm/adchoices

Angel Studios https://Angel.com/HermanJoin the Angel Guild today where you can stream Thank You, Dr. Fauci and be part of the conversation demanding truth and accountability.  Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comBe confident in your portfolio with Bulwark! Schedule your free Know Your Risk Portfolio review. Go to KnowYourRiskPodcast.com today. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/ToddThe new GOLDEN AGE is here!  Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeJenner Furst, director of the latest Angel Studios documentary "Thank You Dr. Fauci" joins the show.Episode Links:Thank You Dr. Fauci | Now Streaming | AngelBREAKING/URGENT: mRNA COVID VACCINES KILLED AT LEAST 10 KIDS, THE FDA REPORTS; An FDA review found the shots to blame for the deaths, FDA's new vaccine chief - Dr. Vinay Prasad - told staffers in an email. The agency will tighten standards on new vaccine approval, Prasad wrote.Fauci's Ebola stuntURGENT: mRNA Covid jabs should NEVER have been approved for children or young adults Pfizer, Moderna, the Biden Administration, and everyone in public health who pushed these for kids and teens have blood on their handsUnmask The Truth | Official Clip | Thank You, Dr. Fauci

What are CEOs across industries doing to build resilience and strong cultures in an age of uncertainty? In this Future of Business series, IdeaCast hosts Alison Beard and Adi Ignatius sat down with four leading CEOs to understand where global business is going. In this episode, host Alison Beard speaks with Noubar Afeyan, the CEO of Flagship Pioneering and Chairman of Moderna. Afeyan shares the organizational models and practices that work best to produce innovation, the difference between managing risk and managing uncertainty, and what separates true breakthrough innovation from everyday, incremental improvements.

“This is a time to reimagine public health and public health/healthcare system integration,” says Dr. Deb Houry, the former chief medical officer for the US Centers for Disease Control and Prevention. In this thoughtful Raise the Line conversation, Dr. Houry reflects on unprecedented federal action in vaccine guidance and other issues since her noteworthy resignation from the CDC in August, and sees a more decentralized landscape emerging where states and localities play a larger role in providing public health recommendations. And while she acknowledges upsides to this shift, she's also concerned what the absence of a national consensus on health standards could mean. “Diseases don't recognize borders, and it's also important that people have equitable access to preventative services, vaccines, and other things,” she tells host Lindsey Smith. Tune in for Dr. Houry's seasoned perspective on this consequential moment in public health, and her encouraging message for learners and early career providers considering a career in the sector.Mentioned in this episode:DH Leadership & Strategy Solutions If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Chuck And Julie Show with Chuck Bonniwell and Julie Hayden Guest, Ray Garcia - CO GOP Chair Brita Horn continues to steer the Colorado Republican Party toward disaster As CO GOP Chair Brita Horn continues to steer the Party toward disaster, grassroots warrior Ray Garcia renews his call for changes in leadership. He joins the show to reveal the latest efforts. Plus shocking FDA memo reveals Moderna knew its COVID 19 vaccine killed children and joined forces with the government to coerce vaccinations anyway.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über drohenden Ärger für Moderna, einen Kurskracher bei MongoDB und fiese Japan-Vibes. Außerdem geht es um Moderna, BioNTech, Novavax, Pfizer, GSK, MongoDB, Cleanspark, Coinbase, Robinhood, Strategy, Bitcoin, Ether, Bayer, Synopsis, Nvidia und The Magnum Ice Cream Company. Die aktuelle "Alles auf Aktien"-Umfrage findet Ihr unter: https://www.umfrageonline.com/c/mh9uebwm Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Em 2025, Data destaca a subida global dos casos de escravidão moderna e reforça o apelo do secretário-geral para ações urgentes que protejam os 50 milhões de vítimas atuais.

Ohne Aktien-Zugang ist's schwer? Starte jetzt bei unserem Partner Scalable Capital. Mit eigenem KI-Chatbot, der dir alle Fragen rund ums Investieren beantwortet. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Goldman Sachs kauft ETF-Anbieter. NVIDIA investiert in Synopsys. Rüstungsaktien fallen wegen Friedensgesprächen. Airbus hat Produktionsprobleme. Moderna & BioNTech kämpfen mit Regulatorik. Coupang hat Datenleck. Bitcoin verliert. Disney gewinnt. Schwierige wirtschaftliche Zeiten. Hohe Inflation. Darunter leiden viele. TJX (WKN: 854854) profitiert. Die Gen Z will schlichtere Luxusuhren. Cartier freut's. Richemont (WKN: A1W5CV) auch. Lohnt ein Investment noch? Diesen Podcast vom 02.12.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Special Report: The Quantum Threshold (December 02, 2025)This special episode dissects the paradigm shift from theoretical quantum physics to engineering reality, triggered by Google's latest hardware and AI advancements.Key Topics & Takeaways:⚡ The Engineering Miracle (Google Willow): Google has unveiled "Willow," a 105-qubit processor that successfully demonstrates the "Threshold Theorem." For the first time, increasing the number of physical qubits (from code distance 3 to 7) has led to an exponential drop in error rates, proving that fault-tolerant quantum computing is physically possible.

At the age of 14, Michaela Janssen Pohl became a caregiver for her mother, who lives with MS. I think most of us can agree that just being a teenager carries with it more than enough challenges. Those adolescent years are the years when just about everything in life starts changing. Imagine adding the responsibilities of being a caregiver to all the other things going on in a 14-year-old girl's life. Michaela joins me this week to explain how she found ways to survive and thrive in what can only be described as a challenging situation for any teenager. We'll also explain why you might want to think a little differently about Giving Tuesday this year. We're sharing all the details about the Phase 2 clinical trial focusing on Moderna's investigational Epstein-Barr vaccine and MS (and we'll explain why that might turn out to be important!) We're talking about how MS impacts women's health issues with this year's winner of the Rachel Horne Prize for Women's Research in Multiple Sclerosis, Dr. Kristen Krysko. And we're sharing the results of the Phase 2 clinical trial for PIPE-307, an investigational remyelination therapy. We have a lot to talk about! Are you ready for RealTalk MS??! It's Giving Tuesday (and why that matters more this year than ever before)  :22 This Week: Becoming a caregiver for a parent with MS when you're 14 years old  3:27 A clinical trial focused on an EBV vaccine and MS is recruiting participants  4:25 Dr. Kristen Krysko discusses MS and women's health issues  7:52 Results from the Phase 2 clinical trial for PIPE-307 remyelination therapy  13:48 Michaela Janssen Pohl shares her story of becoming a caregiver at the age of 14  16:55 Share this episode  33:20 Next week's episode  33:40 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/431 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com DONATE: The National MS Society https://nationalmssociety.org/donate SIGN UP: Become an MS Activist https://nationalmssociety.org/advocacy PARTICIPATE: Phase 2 Clinical Trial for Moderna's EBV Vaccine and MS https://clinicaltrials.gov/study/NCT06735248 Email: WeCareClinicalTrials@modernatx.com JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 431 Guests: Dr. Kristen Krysko, Michaela Janssen Pohl Privacy Policy

El lanzaroteño Jorge Cabrera Luzardo, conocido artísticamente como Jorge Caluz, es cantante, pianista y compositor. Su discapacidad visual, apenas un 10% de visión, nunca le ha frenado a la hora de dedicarse a lo que más le apasiona: la música. Al contrario, potenció desde pequeño su sensibilidad y su oído musical.Comenzó a estudiar piano con tan solo 3 años y a los 15 inició su formación en canto. Más tarde prosiguió estudios superiores en Música Moderna e Interpretación Vocal en Madrid y Londres. Ha actuado en escenarios tan emblemáticos como la Sala Sol de Madrid y, desde hace dos años, ofrece conciertos en solitario.En 2025 ha representado a España en el Certamen Internacional “Low Vision”, considerado el “Eurovisión” de los artistas con discapacidad visual. En esta ocasión nos interpreta en directo una composición propia: Mi forma de ser.Escuchar audio

Neste episódio Rafinha (@rafaverdasca) e Daniel Gomes de Carvalho (@danielgomesdecr) e recebem Luciano Cesar (@lucianocesarcosta) para uma discussão sobre as principais tensões e linhas de análise sobre a Diplomacia Moderna Canal do História Pirata no YouTube: https://www.youtube.com/@historiapirata chave pix: podcast.historiapirata@gmail.com Livro do Prof. Daniel sobre a Revolução Francesa: https://www.editoracontexto.com.br/produto/revolucao-francesa/5105603 Esse episódio foi editado por: Gabriel Campos (@_grcampos)

Australia is known around the world for its rich and diverse First Nations cultures. But when it comes to native title and land rights, you might still wonder what they actually mean. Discover what native title means in Australia, how it began with the Mabo Case, what the Native Title Act does, and why it matters for all Australians. - Australia es conocida en todo el mundo por sus ricas y diversas culturas de las Primeras Naciones. Pero cuando se trata de los títulos nativos y los derechos sobre la tierra, es posible que aún te preguntes qué significan realmente. Descubre qué significa el título nativo en Australia, cómo comenzó con el caso Mabo, qué hace la Ley de títulos nativos y por qué es importante para todos los australianos.

Biological Sciences: modeRNA Hacking the Software of LIFE- Gene Augmentation at the End of Days pt.1 (Agenda 2030)Moderna and its Motto has raised red flags

En este episodio, conversamos con Vanya Thais, periodista y activista católica peruana, sobre temas cruciales que afectan a la Iglesia Católica y al mundo actual. Analizamos el legado del Papa Francisco, la influencia del catolicismo en la política global, la batalla cultural y la guerra espiritual que enfrentan los creyentes, y las leyendas negras que buscan desacreditar a la Iglesia. Vanya comparte su perspectiva sobre cómo los católicos pueden responder a estos desafíos con fe y acción.Temas destacados: • El legado del Papa Francisco y el futuro del papado. • La influencia del catolicismo en la política contemporánea. • La batalla cultural y la guerra espiritual en el mundo actual. • Leyendas negras modernas sobre la Iglesia Católica. • El papel de la mujer en la Iglesia y la sociedad. • La importancia de la educación en la formación de la fe.#VanyaThais #IglesiaCatólica #PapaFrancisco #BatallaCultural #GuerraEspiritual #CatolicismoYPolítica #LeyendasNegras #MujerEnLaIglesia #EducaciónYFe #FeYAcción #CulturaYFe #IglesiaYSociedad #ActivismoCatólico #Perú #FeCatólica #FuturoDelPapado #CatolicismoEnElMundo #RetosDeLaIglesia #PerspectivaCatólica #EstebanFigueroa #JohannaMontenegro #Inquebrantables

Selamat pagi! Today, travel medicine specialists Drs. Paul Pottinger & Chris Sanford answer your travel health questions, including:Myocarditis & Moderna–is the risk real?Is Waymo a safe way to get around?West Nile Virus in France–really?What changes are coming up with regulations for European travel?What should I know about leptospirosis to stay safe?What Travel apps do you recommend?How can I get my health insurance to cover pre-travel office visits?How do you recommend I learn a new language quickly?We hope you enjoy this podcast! If so, please follow us on the socials @germ.and.worm, subscribe to our RSS feed and share with your friends! We would so appreciate your rating and review to help us grow our audience. And, please visit our website: germandworm.com where you can find all our content and send us your questions and travel health anecdotes. Or, just send us an email: germandworm@gmail.com.Our Disclaimer: The Germ and Worm Podcast is designed to inform, inspire, and entertain. However, this podcast does NOT establish a doctor-patient relationship, and it should NOT replace your conversation with a qualified healthcare professional. Please see one before your next adventure. The opinions in this podcast are Dr. Sanford's & Dr. Pottinger's alone, and do not necessarily represent the opinions of the University of Washington or UW Medicine.

The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients—revving up their immune systems to help fight tumors. People with advanced lung or skin cancer who were taking certain immunotherapy drugs lived substantially longer if they also got a Pfizer or Moderna shot within 100 days of starting treatment, according to preliminary research reported in the journal Nature. And it had nothing to do with virus infections. Instead, the molecule that powers those specific vaccines, mRNA, appears to help the immune system respond better to the cutting-edge cancer treatment, concluded researchers from MD Anderson Cancer Center in Houston and the University of Florida. The vaccine “acts like a siren to activate immune cells throughout the body,” said lead researcher Dr. Adam Grippin of MD Anderson. Health Secretary Robert F. Kennedy Jr. has raised skepticism about mRNA vaccines, cutting $500 million in funding for some uses of the technology. But this research team found its results so promising that it is preparing a more rigorous study to see if mRNA coronavirus vaccines should be paired with cancer drugs called checkpoint inhibitors—an interim step while it designs new mRNA vaccines for use in cancer. A healthy immune system often kills cancer cells before they become a threat. But some tumors evolve to hide from immune attack. Checkpoint inhibitors remove that cloak. It's a powerful treatment—when it works. Some people's immune cells still don't recognize the tumor. Messenger RNA, or mRNA, is naturally found in every cell, and it contains genetic instructions for our bodies to make proteins. While best known as the Nobel Prize-winning technology behind COVID-19 vaccines, scientists have long been trying to create personalized mRNA “treatment vaccines” that train immune cells to spot unique features of a patient's tumor. Dr. Grippin and his Florida colleagues had been developing personalized mRNA cancer vaccines when they realized that even one created without a specific target appeared to spur similar immune activity against cancer. This article was provided by The Associated Press.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of significant stories shaping the future of healthcare, from innovative financing strategies to groundbreaking scientific advancements.The biotech industry in 2025 has experienced a notable shift in funding strategies, particularly through the rising trend of royalty financing. This approach, involving the exchange of future drug revenue for immediate capital, has surged to approximately $3.5 billion in disclosed upfront volume in just the first half of the year. According to health economist Julien Willard, this represents a transformative shift from a niche option to a mainstream strategy amid challenging equity and credit markets. Royalty financing provides biotech companies with a lifeline, allowing them to avoid the pitfalls of equity dilution or high-interest debt while retaining control over their clinical developments. Firms like Royalty Pharma and Healthcare Royalty Partners are at the forefront, offering upfront cash for future sales royalties, typically ranging from 2.5% to 7.5%.This trend has accelerated due to economic pressures like low stock valuations and rising interest rates, making traditional funding routes less viable. A closer look at this year's deals reveals a cautious approach among investors, who are focusing on phase 3 trials or candidates awaiting FDA approval rather than early-stage assets. Oncology takes center stage as the leading therapeutic area, accounting for about 70% of total disclosed funding, thanks to its potential for large revenue streams. Other areas like rare genetic diseases and immunology also attract significant attention.Interestingly, even large pharmaceutical companies such as Biogen have ventured into royalty financing—an unconventional move for well-capitalized firms. Biogen's collaboration with Royalty Pharma for lupus drug development illustrates innovative financial engineering by transferring clinical trial risk through milestone-tied payments. As this strategy gains traction globally, especially in cash-strapped regions like Asia, it serves as a crucial tool for companies prioritizing survival and continued innovation amidst financial uncertainties.Turning now to regulatory dynamics and strategic shifts within the industry. The legal controversy between GSK's subsidiary Tesaro and AnaptysBio over Jemperli highlights complexities in collaborative agreements within drug development. Such disputes could reshape how companies negotiate intellectual property rights and revenue sharing in future co-development deals.The FDA's investigation into Takeda's Adzynma following a pediatric patient's death underscores the critical role of post-market surveillance in drug safety. This incident could potentially impact Takeda's market position while emphasizing the need for robust adverse event monitoring systems across biopharmaceutical firms.In Australia, the government's decision to block Cosette's proposed $430 million acquisition of Mayne Pharma reflects increasing scrutiny on foreign investments in healthcare companies, prioritizing national interest. This move signals a growing trend that could reshape global M&A strategies within the sector.Meanwhile, Moderna's strategic financial maneuvering is noteworthy. By securing a $1.5 billion loan aimed at supporting its commercial and R&D endeavors with an eye on breaking even by 2028, Moderna demonstrates its commitment to diversifying its mRNA technology applications beyond COVID-19 vaccines—a move likely to influence innovation trajectories across biotech landscapes. Additionally, Moderna's decision to discontinue three clinical mRNA programs showcases strategic pipeline management amidSupport the show

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a landscape marked by significant scientific advancements, regulatory approvals, and strategic shifts that are reshaping the industry.Starting with Regeneron, the company's ophthalmic drug Eylea HD has recently secured two FDA approvals. These endorsements not only grant a new indication but also introduce a more flexible dosing regimen. This positions Eylea HD competitively against Roche's Vabysmo, highlighting the importance of regulatory navigation and strategic positioning in the pharmaceutical sector. These approvals come after extensive negotiations with both the FDA and third-party manufacturers, emphasizing the intricate processes involved in bringing a drug to market.In oncology, Bayer has achieved an accelerated FDA approval for Hyrnuo, a treatment targeting HER2-mutated non-small cell lung cancer. This move allows Bayer to challenge Boehringer Ingelheim's Hernexeos, underscoring the fiercely competitive nature of the oncology market. Such advancements are driven by innovative treatments that address specific genetic mutations in cancer patients, reflecting a broader trend towards precision medicine.Meanwhile, Moderna is investing heavily in mRNA production capabilities with a new $140 million facility in Norwood, Massachusetts. This development underscores Moderna's commitment to mRNA technology, which gained significant attention during the COVID-19 pandemic. The facility aims to establish robust domestic manufacturing infrastructures to mitigate supply chain vulnerabilities—a critical move considering recent global disruptions.Novartis is also making headlines with its plans for a flagship production hub in North Carolina. This expansion is expected to create 700 jobs and expand its manufacturing footprint by 700,000 square feet, highlighting Novartis's strategic emphasis on scaling up operations to meet growing demands and enhance production efficiency.In another strategic collaboration, Antheia has joined forces with Teva's TAPI division to enhance the commercialization prospects for its biosynthetic pipeline. This alliance marks a significant step toward advancing biologically derived pharmaceuticals, promising to revolutionize drug production through more sustainable and scalable alternatives to traditional chemical synthesis.On the regulatory front, Merck has received broad EU approval for a subcutaneous formulation of Keytruda. This development could significantly expand Keytruda's market reach across Europe, demonstrating how regulatory agility can extend drug lifecycles and maximize therapeutic impact across diverse patient populations.Compliance challenges remain prevalent, as illustrated by Pfizer and Tris Pharma's settlement of allegations related to ADHD medication Quillivant's quality control issues for $41.5 million. This case highlights ongoing efforts to ensure stringent quality standards within pharmaceutical manufacturing processes.Abbott is expanding its diagnostics portfolio through a $23 billion acquisition of Exact Sciences, known for its Cologuard colorectal cancer test. This acquisition indicates a strategic shift towards enhancing diagnostic capabilities alongside therapeutic offerings—a trend increasingly evident in holistic healthcare solutions.GSK is embarking on a $7 billion collaboration with biotechs Quotient and Profound through Flagship Pioneering. This partnership aims to leverage novel protein and genomic technologies to drive innovation in drug discovery and development, illustrating the industry's focus on integrating advanced biotechnological insights into traditional pharmaceutical frameworks.These developments collectively underscore crSupport the show

Australia is known around the world for its rich and diverse First Nations cultures. But when it comes to native title and land rights, you might still wonder what they actually mean. Discover what native title means in Australia, how it began with the Mabo Case, what the Native Title Act does, and why it matters for all Australians. - A Austrália é conhecida em todo o mundo pela rica e diversa cultura dos Povos das Primeiras Nações Australianas. Mas, quando se fala em "native title" e direitos sobre a terra, continua a impor-se a pergunta sobre o que significam realmente. O que é, então, o "native title"? E como surgiu?

“My most powerful content is when I lead with my voice as a mom because I have the same concerns about keeping my kids safe as my audience does. It's a powerful and effective way to find common ground with people,” says Dr. Jess Steier, a popular public health scientist and science communicator seeking to bridge divides and foster trust through empathetic, evidence-based communication. Dr. Steier has several platforms from which to do this work, including  Unbiased Science --  a communication hub that uses multiple social media platforms and other communications channels to share validated health and science information -- and as executive director of the Science Literacy Lab, a nonprofit organization dedicated to reaching a diverse audience seeking clarity and reliable information on scientific topics. “The science is less than half the battle,” she explains. “It's about how to communicate with empathy.”Join Raise the Line host Lindsey Smith for a valuable conversation that explores:What sources Dr. Steier relies on to validate informationHow she uses “escape room” exercises to train clinicians on empathetic communicationWhy tailored, story-driven messages reach audiences more effectively than facts.Mentioned in this episode:Unbiased Science If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Esther 5... La influencia del mundo en la mujer moderna [Ubk7AJZhEA4] by G3:16 Satélite

“I realized that rather than talking one-to-one with patients in the exam room, you could talk one-to-many on social media,” says Dr. Kevin Pho, explaining the origins of KevinMD, the highly influential information sharing site he created for physicians, medical students and patients twenty years ago. Since then, KevinMD has become a valuable space for clinicians and patients to share stories and perspectives on topics from burnout and moral injury to technology and trust. In this conversation with Raise the Line host Michael Carrese, Dr. Pho reflects on the dual paths that have defined his career: as a practicing internal medicine physician and as one of healthcare's most trusted online voices. And despite the challenges of doing so, Dr. Pho encourages other medical providers to follow his lead. “Patients are going online, and if physicians are not there, they're going to get information that's perhaps politically-driven or simply inaccurate.”This thoughtful conversation also explores: How social media has reshaped health communicationThe risks and rewards for clinicians of having an online presence Why medical schools should teach negotiating skillsMentioned in this episode:KevinMDEstablishing, Managing and Protecting Your Online Reputation If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

En el programa 'Herrera en COPE',  Alberto Herrera y Mar Amate han analizado un fenómeno creciente que refleja un cambio profundo en los hábitos de la sociedad española. España consume ya más de 700 millones de kilos de platos preparados al año, lo que supone un aumento de un 50% más que hace solo tres años. Este dato destapa la consolidación de la llamada 'cultura del atajo', una tendencia impulsada por la falta de tiempo y el agotamiento generalizado.El debate, como ha planteado Amate en antena, ya no es "por qué somos tan vagos", sino "por qué estamos tan cansados", una pregunta que resuena en una sociedad donde la frase "no tengo tiempo" se ha vuelto tan común como un saludo. Este sentir general justifica atajos antes impensables, como comprar huevos ya cocidos y pelados —anécdota de una amiga de la propia comunicadora—, judías verdes de bote o garbanzos ya cocidos, un recurso que el mismo Herrera ha admitido utilizar.La ciencia ofrece una explicación a ...

What does it really take to launch a big idea? One that can change your career, business, or even the world? Is being a visionary enough, or is there a hidden formula for success? Guest Jen Kem says it's all about building the right "unicorn team." But here's the twist: even if you're a solopreneur or running a small business—like me—this book is still for you. Jen's framework isn't about having a massive team; it's about understanding the roles and energies you bring to your work and how to fill in the gaps to achieve success faster and with less burnout.Jen is a brand strategist, entrepreneur, and author of Unicorn Team: The Nine Leadership Types You Need to Launch Your Big Ideas with Speed and Success. With a career working on iconic initiatives for companies like Microsoft, Coca-Cola, and Oracle, she's now revealing how big ideas succeed—not just through visionaries, but through the right mix of leaders who execute and get results.We'll learn how to identify your own leadership type, how even a solo effort can become a "team" by leveraging the right resources, and hear the inspiring story of how a small team at Moderna outpaced industry giants to lead the charge on a life-saving vaccine. Hosted on Acast. See acast.com/privacy for more information.

Con 150mila addetti, molti dei quali immigrati, il settore delle pulizie è una delle colonne invisibili dell'economia nazionale. Abbiamo raccolto testimonianze di chi opera in un comparto fondamentale, ma che l'Australian Human Rights Commission ha inserito tra quelli a rischio di “modern slavery”.

“We've created this ecosystem where the vast majority of information on social media, particularly in nutrition science, is inaccurate or misleading,” says Dr. Jessica Knurick, a registered dietitian and Ph.D. in nutrition science specializing in chronic disease prevention. As you'll learn on this episode of Raise the Line with host Lindsey Smith, countering that trend has become Dr. Knurick's focus in the past several years, and her talent for translating complex scientific information into practical guidance has attracted a large following on social media. Beyond equipping her audience with the tools to think critically and make informed choices for themselves, she also wants them to make the connection between the generally poor health status of most Americans with public policies on food and health and advocate for more beneficial approaches. “We can create systems that put the most people in the position to succeed versus putting the most people in the position to fail.” Tune in to learn from this trusted voice on nutrition, food policy, and public health as she shares her perspectives on: Strategies for risk reduction and behavior changeWhat can rebuild trust in medical information How you can cut through the noise and spot misinformation onlineMentioned in this episode:Dr. Knurick's WebsiteTikTok ChannelInstagram FeedFacebook Page If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

En Raza Deportiva Rafa Ramos y Eli Patiño analizan la ‘resurrección' de Chicharito y profundizan en las dos caras de Javier Hernández, además reaccionan a la jornada 17 de la Liga MX: triunfo de Pumas, derrota del América y la victoria de Guadalajara sobre Monterrey. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Unredacted government emails obtained by Senator Ron Johnson show that health officials identified a myocarditis risk from mRNA vaccines months before informing the public. While Pfizer and Moderna were quietly notified, Americans were not. Jefferey Jaxen breaks down the evidence and new studies showing how mRNA and spike proteins affect heart tissue. Del Bigtree calls it a defining moment for accountability in public health.Become a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.